[1]Patent:WO2007/53452,2007,A1.Locationinpatent:Page/Pagecolumn108-109
[1]CurrentPatentAssignee:HANDANWINCONDRUGINTERMEDIATERESDEV;SHANGHAIWINCONCHEMRD-CN103242240,2016,BLocationinpatent:Paragraph0091-0095
[1]CurrentPatentAssignee:HANDANWINCONDRUGINTERMEDIATERESDEV;SHANGHAIWINCONCHEMRD-CN103242240,2016,BLocationinpatent:Paragraph0081-0085
[1]CurrentPatentAssignee:SHANGHAIWINCONCHEMRD;HANDANWINCONDRUGINTERMEDIATERESDEV-CN103242240,2016,B
[2]CurrentPatentAssignee:SHANGHAIWINCONCHEMRD;HANDANWINCONDRUGINTERMEDIATERESDEV-CN103242240,2016,B
[3]CurrentPatentAssignee:SHANGHAIWINCONCHEMRD;HANDANWINCONDRUGINTERMEDIATERESDEV-CN103242240,2016,B
Title: The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Journal: Experimental hematology 20120801
Title: Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research 20111201
Title: Janus kinase 2 regulates Bcr-Abl signaling in chronic myeloid leukemia.
Journal: Leukemia 20110301
Title: TG101209, a novel JAK2 inhibitor, has significant in vitro activity in multiple myeloma and displays preferential cytotoxicity for CD45+ myeloma cells.
Journal: American journal of hematology 20100901
Title: Prolactin-induced Jak2 phosphorylation of RUSH: a key element in Jak/RUSH signaling.
Journal: Molecular and cellular endocrinology 20100830
Title: Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.
Journal: Blood 20091203
Title: TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Journal: Leukemia 20070801
Title: Pardanani A, et al. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations. Leukemia. 2007 Aug;21(8):1658-68.
Title: Ma AC, et al. A novel zebrafish jak2a(V581F) model shared features of human JAK2(V617F) polycythemia vera. Exp Hematol. 2009 Dec;37(12):1379-1386.e4.
Title: Sun Y, et al. Inhibition of JAK2 signaling by TG101209 enhances radiotherapy in lung cancer models. J Thorac Oncol. 2011 Apr;6(4):699-706
Title: Cuesta-Dominguez A, et al. Transforming and tumorigenic activity of JAK2 by fusion to BCR: molecular mechanisms of action of a novel BCR-JAK2 tyrosine-kinase. PLoS One. 2012;7(2):e3245
